1Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children[J]. J Am Acad Dermatol, 2002, 47(4): 548-552.
2Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin[J]. Science, 1998, 282(5388): 490-493.
2[1]Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience[J]. Dermatology, 2001, 203(1): 45-59.
3[2]Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal neerolysis by blockade of CD95 with human intravenous immunoglobulin[J]. Science, 1998, 282(5388): 490-493.
2Viard I,WehrliP,Bullani R.et al.Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.Science 1998;282:490-493.
3Bachot N,Revui J,Roujeau JC.Intravenous immunoglobulin treatment for Stenvens-Johnson syndrome and toxic epidermal necrolysis:a prospective noncompamtlve study showing no benefit on mortality or progression.Arch Dermatol 2003;139:33-36.
4Rago JV,Vath GM,Bohach GA,et al.Mutational analysis of the superantigen staphylococal extoliative toxic A(ETA).Immunol 2000;164:2207-2213.
